Body adiposity index versus body mass index and other anthropometric traits as correlates of cardiometabolic risk factors. by Lichtash, Charlene T et al.
UCLA
UCLA Previously Published Works
Title
Body adiposity index versus body mass index and other anthropometric traits as correlates 
of cardiometabolic risk factors.
Permalink
https://escholarship.org/uc/item/159873r3
Journal
PloS one, 8(6)
ISSN
1932-6203
Authors
Lichtash, Charlene T
Cui, Jinrui
Guo, Xiuqing
et al.
Publication Date
2013
DOI
10.1371/journal.pone.0065954
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Body Adiposity Index versus Body Mass Index and Other
Anthropometric Traits as Correlates of Cardiometabolic
Risk Factors
Charlene T. Lichtash1, Jinrui Cui2, Xiuqing Guo2, Yii-Der I. Chen2, Willa A. Hsueh3, Jerome I. Rotter1,2,
Mark O. Goodarzi1,2,4,5*
1Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, United States of America, 2Medical Genetics Institute, Cedars-Sinai Medical Center, Los
Angeles, California, United States of America, 3Diabetes Research Center, Division of Diabetes, Obesity and Lipids, Methodist Hospital Research Institute, Houston, Texas,
United States of America, 4Division of Endocrinology, Diabetes and Metabolism, Cedars-Sinai Medical Center, Los Angeles, California, United States of America,
5Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, United States of America
Abstract
Objective: The worldwide prevalence of obesity mandates a widely accessible tool to categorize adiposity that can best
predict associated health risks. The body adiposity index (BAI) was designed as a single equation to predict body adiposity
in pooled analysis of both genders. We compared body adiposity index (BAI), body mass index (BMI), and other
anthropometric measures, including percent body fat (PBF), in their correlations with cardiometabolic risk factors. We also
compared BAI with BMI to determine which index is a better predictor of PBF.
Methods: The cohort consisted of 698 Mexican Americans. We calculated correlations of BAI, BMI, and other anthropometric
measurements (PBF measured by dual energy X-ray absorptiometry, waist and hip circumference, height, weight) with
glucose homeostasis indices (including insulin sensitivity and insulin clearance from euglycemic clamp), lipid parameters,
cardiovascular traits (including carotid intima-media thickness), and biomarkers (C-reactive protein, plasminogen activator
inhibitor-1 and adiponectin). Correlations between each anthropometric measure and cardiometabolic trait were compared
in both sex-pooled and sex-stratified groups.
Results: BMI was associated with all but two measured traits (carotid intima-media thickness and fasting glucose in men),
while BAI lacked association with several variables. BAI did not outperform BMI in its associations with any cardiometabolic
trait. BAI was correlated more strongly than BMI with PBF in sex-pooled analyses (r = 0.78 versus r = 0.51), but not in sex-
stratified analyses (men, r = 0.63 versus r = 0.79; women, r = 0.69 versus r = 0.77). Additionally, PBF showed fewer correlations
with cardiometabolic risk factors than BMI. Weight was more strongly correlated than hip with many of the cardiometabolic
risk factors examined.
Conclusions: BAI is inferior to the widely used BMI as a correlate of the cardiometabolic risk factors studied. Additionally,
BMI’s relationship with total adiposity may not be the sole determinate of its association with cardiometabolic risk.
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Introduction
The prevalence of obesity worldwide and across age groups has
made it a focus of much investigative research. In the United
States, the prevalence of obesity has been estimated at approx-
imately one-third of the population, with the combined proportion
of overweight and obese individuals encompassing approximately
two thirds of the country [1]. Obesity is associated with an
increased incidence of poor health outcomes, including cardio-
vascular disease, hypertension, diabetes mellitus, dyslipidemia,
osteoarthritis, and certain cancers [2].
The most widely used method to categorize overweight and
obese individuals is the body mass index (BMI, (weight in
kilograms)/(height in meters)2), first named the Quetelet index
and described by Adolphe Quetelet in 1832 [3]. In 1998, the
National Heart, Lung, and Blood Institute of the National
Institutes of Health (NIH) published clinical guidelines in which
BMI was used in the systematic classification of overweight and
obese individuals [4].
However, BMI is an imperfect measure of body adiposity. The
weight term in BMI does not distinguish between muscle mass and
fat mass. Furthermore, BMI has been shown to be age-, sex-, and
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in some cases, race-, dependent [5,6]. At equivalent BMIs, women
have significantly greater amounts of total body fat than men, and
older individuals have significantly greater amounts of total body
fat than those who are younger [5,6]. Finally, it does not describe
the depot of total fat in a person. Despite these disparities,
however, the same BMI cutpoints for overweight and obesity are
often applied across sex and age groups.
In May 2011, Bergman et al. introduced a new parameter, the
body adiposity index (BAI, (hip circumference in centimeters)/
(height in meters)1.5–18), derived via analyses of Mexican-
American subjects, and validated in African-Americans [7].
Among its proposed advantages, the BAI presents a method of
estimating body adiposity without requiring assessment of body
weight, offering a simple-to-use tool that can be accessed globally
[7]. Additionally, the demonstration of similar linear relationships
between BAI and percent body fat (PBF) in men and women
suggests that sex-specific adjustments of BAI as an estimate of PBF
may not be necessary [7].
Several subsequent studies evaluated BAI as a predictor of body
fat composition, yielding inconsistent results. While BAI was more
strongly correlated than BMI with dual-energy X-ray absorpti-
ometry (DXA)-derived PBF in sex-pooled analyses [8,9], results
have varied in sex-stratified analyses, with BAI being similarly
correlated [8,10] or less correlated [9] than BMI with PBF.
Conflicting results have also been observed in states of extreme
adiposity; BAI was more correlated than BMI with PBF in women
with familial partial lipodystrophy [11]. In contrast, in a study of
severely obese women, BMI, but not BAI, was significantly
correlated with DXA-derived PBF [12].
To date, several published studies have examined BAI’s
association with health risks or outcomes [9,13,14,15,16,17,18].
Findings of the studies reported thus far illustrate the need for
further clarification on the clinical utility of BAI as a measure of
body adiposity and correlate of disease [13,19]. The goal of our
study was to define the correlations of BAI, BMI, and other
measured anthropometric variables with (a) glucose homeostasis
traits, (b) lipid parameters, (c) cardiovascular traits, and (d)
biomarkers. In cases wherein both BMI and BAI were associated
with a trait, we statistically assessed whether one was more strongly
associated than the other, to elucidate which may be more
associated with cardiometabolic risk. A secondary aim of our study
was to examine the associations of the various anthropometric
variables with PBF, and to determine the correlation of PBF itself
with cardiometabolic risk factors.
Materials and Methods
Study Subjects
Metabolic and cardiovascular phenotypes were assessed in
participants of the UCLA/Cedars-Sinai Mexican-American Cor-
onary Artery Disease (MACAD) project, a study of Mexican-
American families from Los Angeles [20,21]. To be classified as
Mexican and qualify for the study, subjects had to report at least
three grandparents of Mexican origin. In the present report, 698
subjects from 193 families (299 male and 399 female) with BAI
values were studied, comprising adult offspring (age 18 or older) of
probands with coronary artery disease, and the spouses of those
offspring (if available) [20,21]. By design, offspring were free of
overt cardiovascular and metabolic disease, thus avoiding second-
ary changes in phenotype caused by overt disease.
Ethics Statement
All studies were approved by Human Subjects Protection
Institutional Review Boards at UCLA and Cedars-Sinai Medical
Center. All subjects gave written informed consent prior to
participation.
Phenotyping Procedures
Subjects underwent a phenotyping protocol that included
testing of glucose homeostasis indices, lipid parameters, cardio-
vascular traits, and biomarkers. In the original MACAD study
design, a three-day phenotyping protocol was to take place within
one week for each subject in the offspring generation. As executed,
the time window for completion of all phenotyping ranged from
one week to several years. The median time to completion of
studies was 25.5 days; 81% of subjects completed phenotyping
within 6 months. Only subjects completing studies within one year
were included in the current study. On one day, fasting blood was
obtained, followed by a 75 g oral glucose tolerance test (OGTT).
On a separate day, B-mode ultrasound was performed for
measurement of common carotid artery intima-media thickness
(IMT) and dual-energy X-ray absorptiometry (DXA) scan was
performed to assess body fat distribution. On a further day, a
euglycemic-hyperinsulinemic clamp was performed.
During the clamp, a priming dose of human insulin (Novolin,
Clayton, NC) was given and followed by infusion for 120 minutes
at a constant rate (60 mU?m22?min21) with the goal of achieving
a steady state plasma insulin concentration of 100 mIU/ml or
greater [20,22]. Blood was sampled every 5 minutes, and the rate
of 20% dextrose coinfused was adjusted to maintain plasma
glucose concentrations at 95 to 100 mg/dl. The glucose infusion
rate (M value, mg?m22?min21) over the last 30 minutes of steady-
state insulin and glucose concentrations reflects glucose uptake by
all tissues of the body (primarily insulin-mediated glucose uptake in
muscle) and is therefore directly correlated with tissue insulin
sensitivity [22]. The insulin sensitivity index (M/I,
mg?m22?min21?mIU21?mL) was calculated as M divided by the
steady state plasma insulin level (I). The metabolic clearance rate
of insulin (MCRI, mL?m22?min21) was calculated as the insulin
infusion rate divided by the steady state insulin level of the
euglycemic clamp, as previously described [22,23].
Fasting lipid parameters including low-density lipoprotein
cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-
C), and triglycerides (TG), were examined in this study.
Cardiovascular traits included systolic and diastolic blood
pressure (SBP and DBP) and carotid intima-media thickness
(IMT) [24,25]. Carotid artery images were obtained by high-
resolution B-mode ultrasound using the Toshiba SSH-140A
ultrasound system with a 7.5-MHz probe, at the University of
Southern California Atherosclerosis Research Unit [26]. The IMT
measure represents the distance between the blood-intima and
media-adventitia echoes taken at the right distal common carotid
artery [26]. Values are reported as the average of 80 to 100
individual IMT measurements made over 1 cm of the right distal
common carotid artery [26].
Fasting biomarkers included C-reactive protein (CRP), adipo-
nectin, and plasminogen activator inhibitor-1 (PAI-1) levels.
Also tested were percent body fat (PBF) measured by DXA, as
well as anthropometric indices (BMI, BAI, height, waist circum-
ference, weight, and hip circumference) [27].
Data Analysis
Log-transformed (BAI, BMI, weight, hip, HDL-C, TG, carotid
IMT, adiponectin, CRP, 2-hour glucose, fasting insulin) or square-
root transformed (M/I, MCRI, PAI-I) trait values were used to
normalize the distribution for statistical analyses. We computed
correlation coefficients (r) between the cardiometabolic phenotypes
mentioned above, and the following measures: BMI, BAI, waist,
BAI and Cardiometabolic Risk Factors
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hip, height, weight, and PBF and the P values indicating the
difference of the correlation coefficients from zero. Correlation
coefficients were also used to compare anthropometric measures in
their degree of association with PBF. Hotelling’s t-test was used to
determine whether correlation coefficients were significantly
different. P values of ,0.05 were considered significant.
Because the MACAD cohort consists of families, we also
computed correlation coefficients using generalized estimating
equations (GEE), adjusting for familial relationships. The weighted
GEE1 [28] was computed assuming an exchangeable correlation
structure and using the sandwich estimator of the variance to
account for familial correlation present in family data.
Results
General Characteristics
The clinical characteristics of the 698 subjects are shown in
Table 1. BMI did not differ significantly by gender, while BAI was
higher in women than in men. Of the anthropometric measure-
ments, waist circumference, weight, and height were significantly
higher in men, while hip circumference and PBF were higher in
women. With the exception of MCRI, fasting insulin, and PAI-1,
all of the cardiovascular and metabolic phenotypes differed
significantly between men and women. Men had more adverse
lipid and cardiovascular profiles, while no clear pattern was
observed within the glucose homeostasis and biomarker categories.
Correlations of Anthropometric Measurements with
Cardiometabolic Risk Factors
We found that waist circumference, weight, and BMI were
significantly correlated with all lipid parameters, glucose homeo-
stasis traits, cardiovascular traits, and biomarkers, with the
exception of carotid IMT, LDL-C, and fasting glucose in men
(Table 2). Hip circumference was correlated with fewer of the
cardiometabolic variables; lack of correlation was found with DBP
and LDL-C in both sex-pooled and sex-stratified analyses, and
with 2-hour glucose, fasting glucose, adiponectin levels, and
carotid IMT in men. Comparatively, height showed the least
number of significant relationships with the cardiometabolic
variables. BAI and PBF shared a comparable pattern of lack of
correlation, with neither having significant associations with LDL-
C, TG, fasting glucose, carotid IMT, adiponectin, and SBP in sex-
pooled analyses, as well as adiponectin in women and carotid IMT
in men. We also conducted correlation analyses taking family
relationships into account, and found that the correlation
coefficients were essentially the same (Table S1).
Comparison of the Correlations of BAI and BMI with
Cardiometabolic Risk Factors
Comparison of BAI and BMI in the strength of their
correlations with cardiometabolic traits (Table 3) revealed the
following. BMI was more strongly correlated than BAI with TG,
M/I, fasting insulin and SBP in all analyses (both sex-pooled and
sex-stratified). BMI was also more strongly correlated than BAI
with LDL-C, HDL-C, MCRI, fasting glucose, carotid IMT, DBP,
adiponectin, and PAI-1 in sex-pooled analyses; with HDL-C, 2-
hour glucose, DBP, CRP, and PAI-1 in men; and with MCRI,
carotid IMT, CRP, and adiponectin in women. BMI and BAI
were similar in the strength of their correlations with 2-hour
glucose and CRP in sex-pooled data; with MCRI, fasting glucose,
LDL-C, adiponectin, carotid IMT in men; and with LDL-C,
HDL-C, 2-hour glucose, fasting glucose, DBP, and PAI-1 in
women.
Comparison of the Correlations of Hip Circumference
and Weight with Cardiometabolic Risk Factors
We compared the two variables that distinguish the calculations
of BAI and BMI, namely hip circumference and weight,
respectively (Table S2). Weight was more strongly correlated than
hip circumference with TG and SBP in all analyses (both sex-
pooled and sex-stratified); in sex-pooled data with LDL-C, HDL-
C, carotid IMT, DBP, and adiponectin; in men with 2-hour
glucose, DBP, and PAI-1; and in women with M/I, MCRI, fasting
insulin, CRP and adiponectin. Hip circumference outperformed
weight in the strength of its association with only CRP in pooled
data. Hip circumference and weight were similarly associated with
all other cardiometabolic traits.
Comparison of the Correlations of Anthropometric
Variables with PBF
Comparison of the various anthropometric variables in their
ability to predict PBF is displayed in Table 2. BAI outperformed
BMI in the strength of its correlation with DXA-derived PBF in
sex-pooled analysis; however, when data was sex-stratified, BAI
was weaker than BMI in predicting PBF in men and women.
Figure 1 illustrates these findings. The larger percentage of
overlapping data points between men and women when PBF is
Table 1. Clinical characteristics of the study cohort.
Women
(n=399)
Men
(n =299) P value
Age (yr) 34.0 (13.0) 34.0 (14.0) 0.998
BMI (kg/m2) 28.3 (7.0) 28.6 (5.7) 0.78
BAI (%) 35.4 (8.3) 28.5 (5.1) ,0.0001
Waist Circumference (cm) 89.0 (17.3) 96.5 (13.2) ,0.0001
Hip Circumference (cm) 104.5 (15.4) 103.3 (10.9) 0.0032
Weight (kg) 69.4 (17.9) 82.0 (17.7) ,0.0001
Height (cm) 157.0 (6.9) 170.0 (7.9) ,0.0001
PBF (%) 38.3 (7.7) 24.9 (6.3) ,0.0001
M/I (mg?m22?min21?mIU21?mL) 1.7 (1.2) 1.9 (1.6) 0.0037
MCRI (mL?m22?min21) 468.1 (128.7) 470.0 (137.4) 0.75
Fasting glucose (mmol/L) 5.05 (0.72) 5.32 (0.64) 0.0028
2-hour glucose (mmol/L) 6.38 (2.41) 5.77 (2.64) 0.0001
Fasting insulin (pmol/L) 74.4 (51.0) 67.8 (46.8) 0.61
LDL-C (mmol/L) 2.70 (0.92) 2.91 (1.04) 0.0008
HDL-C (mmol/L) 1.22 (0.41) 1.06 (0.34) ,0.0001
TG (mmol/L) 1.12 (0.85) 1.50 (1.21) ,0.0001
Carotid IMT (mm) 0.63 (0.1) 0.66 (0.1) 0.0086
SBP (mmHg) 109.3 (16.3) 116.7 (17.3) ,0.0001
DBP (mmHg) 64.7 (12.0) 69.3 (10.8) ,0.0001
CRP (mg/L) 2.0 (2.4) 1.1 (1.2) ,0.0001
Adiponectin (mg/mL) 7.8 (4.6) 6.3 (3.3) 0.0002
PAI-1 (ng/mL) 33.2 (26.9) 34.6 (31.0) 0.29
Data are medians (interquartile range).
BAI, body adiposity index; BMI, body mass index; Carotid IMT, carotid intima-
media thickness; CRP, C-reactive protein; DBP, diastolic blood pressure; HDL-C,
high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol;
MCRI, metabolic clearance rate of insulin; M/I, insulin sensitivity index from the
euglycemic-hyperinsulinemic clamp; PAI-1, plasminogen activator inhibitor-1;
PBF, percent total body fat; SBP, systolic blood pressure; TG, triglycerides.
doi:10.1371/journal.pone.0065954.t001
BAI and Cardiometabolic Risk Factors
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plotted against BAI leads to greater correlation between BAI and
PBF than between BMI and PBF (r = 0.78 versus r = 0.51;
P,0.0001) in sex-pooled analyses. However, in sex-stratified data,
correlations with PBF were greater for BMI than for BAI (in men,
r = 0.79 versus r = 0.63, P,0.0001; in women, r = 0.77 versus
r = 0.69, P,0.0001) (Figure 1). Similarly, when DXA-derived total
fat mass was examined, both BMI and BAI correlated with this
measure. However, BMI was stronger than BAI in its correlation
with total fat mass in both sex-pooled (r = 0.84 versus r = 0.71;
P,0.0001) and sex-stratified analyses (in men, r = 0.88 versus
r = 0.61, P,0.0001; in women, r = 0.91 versus r = 0.71,
P,0.0001).
After BAI, height was the second strongest correlate with PBF in
sex-pooled data (r =20.54). However, height lost its correlation
with PBF in sex-stratified analyses (Figure S1); conversely, waist,
hip, weight, and BMI all strengthened in their correlations with
PBF in sex-stratified analyses.
Discussion
We found that the cardiometabolic disease risk factors were
more consistently correlated with BMI, waist circumference, and
weight than with BAI. In cases wherein significant correlations
were found, BAI was either similar to, or weaker than, BMI in the
strength of these associations. Thus, our results show that with
regards to its utility as a correlate of the cardiometabolic risk
factors measured in our study, BAI is similar or inferior to the
currently widely used BMI.
Our study is one of a growing number that have assessed the
strength of BAI’s association with cardiometabolic risk factors
[9,13,14,15,16,17,18,29]. We included three variables that have
not yet been studied with regards to their correlation with BAI,
namely, carotid IMT, plasminogen activator inhibitor-1, and
metabolic clearance rate of insulin from the euglycemic clamp.
Only three other studies besides ours utilized a statistical test to
compare correlation coefficients between anthropometric mea-
sures of body adiposity and cardiometabolic risk factors [9,17,18].
One found that waist circumference and BMI were more strongly
correlated than BAI with OGTT-derived insulin sensitivity and
type 2 diabetes risk [9]. The second found that BMI and waist
circumference were superior to BAI in the strength of their
correlations with most of the seven cardiovascular risk variables
studied (LDL-C, HDL-C, TG, insulin, fasting glucose, SBP, and
DBP); this superiority of BMI and waist circumference was upheld
also when data was stratified by sex and age [17]. There was no
case in which BAI was found to be superior to BMI or waist with
regards to its correlative strength with cardiovascular risk variables
[17]. Finally, the third of these studies found that while BAI was
superior to BMI in its correlation with measures of leptin, BMI
was more strongly correlated than BAI with adiponectin levels,
HDL-C, TG, and glucose homeostasis traits (insulin, fasting
glucose, and homeostasis model assessment of insulin resistance)
[18].
Additional studies compared correlations of BAI and BMI with
cardiometabolic traits, without formal statistical comparison of the
correlation coefficients. One reported that regardless of glycemic
status (euglycemic, impaired fasting glucose, impaired glucose
tolerance, or type 2 diabetes mellitus), BAI had the weakest
correlation with fasting glucose, 2-hour glucose, SBP, and DBP, as
compared with other indices of adiposity (waist circumference,
waist-to-hip ratio, waist-to-height ratio, and BMI) [14]. A study of
obese post-menopausal women examined BAI’s ability to detect
changes in cardiometabolic risk factors after a weight loss
intervention [13]. The study found that the percent change in
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Table 3. Comparison of correlation coefficients between cardiometabolic risk factors and BMI versus BAI.
Variable BMI correlation coefficient BAI correlation coefficient P valuea
SEX-POOLED
PBF 0.51 0.78 ,0.0001
LDL-C 0.14 0.033 0.0006
HDL-C 20.27 20.008 ,0.0001
TG 0.32 0.054 ,0.0001
M/I 20.46 20.37 0.001
MCRI 20.22 20.15 0.019
Fasting Glucose 0.17 0.064 0.0006
2-hour Glucose 0.26 0.25 0.72
Fasting Insulin 0.55 0.35 ,0.0001
Carotid IMT 0.17 0.035 ,0.0001
SBP 0.25 20.002 ,0.0001
DBP 0.12 20.093 ,0.0001
CRP 0.46 0.44 0.52
Adiponectin 20.23 20.011 ,0.0001
PAI-1 0.37 0.21 ,0.0001
MEN
PBF 0.79 0.63 ,0.0001
LDL-C 0.14 0.15 0.82
HDL-C 20.32 20.21 0.0066
TG 0.36 0.23 0.0012
M/I 20.50 20.42 0.038
MCRI 20.23 20.27 0.42
Fasting Glucose 0.11 0.084 0.58
2-hour glucose 0.26 0.17 0.046
Fasting Insulin 0.6 0.46 ,0.0001
Carotid IMT 0.058 0.008 0.25
SBP 0.3 0.16 0.0008
DBP 0.13 20.009 0.0012
CRP 0.29 0.2 0.029
Adiponectin 20.23 20.21 0.54
PAI-1 0.4 0.25 0.0002
WOMEN
PBF 0.77 0.69 ,0.0001
LDL-C 0.16 0.12 0.27
HDL-C 20.27 20.21 0.054
TG 0.33 0.24 0.0078
M/I 20.45 20.34 0.0004
MCRI 20.22 20.12 0.0014
Fasting Glucose 0.22 0.2 0.53
2-hour glucose 0.27 0.23 0.23
Fasting Insulin 0.52 0.38 ,0.0001
Carotid IMT 0.25 0.18 0.042
SBP 0.25 0.17 0.011
DBP 0.12 0.07 0.16
CRP 0.58 0.45 ,0.0001
Adiponectin 20.25 20.12 ,0.0001
PAI-1 0.35 0.34 0.67
Correlation coefficients that are significantly greater are highlighted in bold.
aP values from Hotelling’s T-test.
doi:10.1371/journal.pone.0065954.t003
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BAI following weight loss was significantly associated with percent
changes in CRP and leptin, but not with percent change in any of
the other cardiometabolic risk factors examined (total cholesterol,
HDL-C, TG, fasting glucose, clamp-derived insulin sensitivity,
SBP, or DBP) [13]. A study examining correlation coefficients
between several anthropometric measures and metabolic risk
factors (HDL-C, LDL-C, TG, fasting glucose, SBP, and DBP)
concluded that BMI, waist circumference, waist-to-height ratio,
and waist-to-hip ratio were all better correlated than BAI with the
risk factors measured [16]. In a biracial cohort, anthropometric
measures, including BAI, were found to be similarly correlated
with most cardiovascular risk factors; however, BAI lacked
correlation with LDL-C and total cholesterol in African-American
women, and with SBP and DBP in African American men [15].
Finally, in a cohort of obese individuals classified as insulin
resistant (homeostasis model assessment of insulin resistance
(HOMA-IR) .2.5) and insulin sensitive, BAI and BMI differed
in their correlations with cardiometabolic risk factors [29]. In each
individual group, as well as combined, BAI was correlated with
serum adiponectin, leptin, and CRP levels; however, no correla-
tion was found between BAI and insulin levels or HOMA-IR.
BMI, on the other hand, was not correlated with adiponectin
levels in any group, but was correlated with leptin, CRP, insulin,
and HOMA-IR in the insulin-resistant group [29].
In our study, BAI was significantly associated with several of the
cardiometabolic risk factors, and in several cases performed
similarly to BMI in the strength of its correlations with these risk
factors (Table 3). Within the four categories examined (glucose
homeostasis traits, lipid parameters, cardiovascular traits, and
biomarkers), there was no clear pattern of association, or lack
thereof, with respect to BAI. Further, with certain variables
studied (e.g. LDL-C, TG, fasting glucose, carotid IMT, SBP, and
adiponectin), no correlation was found with either BAI or PBF
when analyzing sex-pooled data; in most cases, correlations of BAI
and PBF with these traits were only revealed when the data was
sex-stratified. This may be explained by differences between men
and women with respect to these variables, as is demonstrated in
the clinical characteristics of our cohort (Table 1). Nevertheless,
comparisons of BMI and BAI with respect to their correlations
with these variables within sex-stratified data showed that BMI
was superior to BAI in its associations with SBP and TG in both
men and women, as well as adiponectin and carotid IMT in
women. BMI and BAI were similar in their associations with LDL-
C and fasting glucose in sex-stratified analyses. Therefore,
variation between the data in men and women with respect to
BAI is unlikely to fully account for the relative weakness of its
associations with cardiometabolic risk factors.
To understand the differences between BAI and BMI in the
strength of their correlations with cardiometabolic risk factors, we
compared hip and weight, the two variables that differ in the
calculations of these adiposity indices. We found that weight was
more associated with many of the cardiometabolic risk factors
examined, consistent with the findings comparing BAI and BMI.
The results of our study illustrate the complexity of the task of
identifying accurate markers of cardiometabolic risk factors
associated with obesity. We found that PBF was less consistently
correlated with several of the cardiometabolic risk factors than
BMI. This suggests that BMI’s relationship with total adiposity
may not be the sole determinate of its relationship with
cardiometabolic risk. Further research is needed to clarify the
characteristics of anthropometric variables that determine their
associations with cardiometabolic risk factors and disease.
We also aimed to identify a single anthropometric measurement
or index that most accurately predicted body adiposity as
measured by DXA. While BAI did correlate most strongly with
PBF in sex-pooled data analyses, BMI proved the most accurate
tool to predict PBF in men and women in sex-stratified analyses, a
finding supported in a recent study performed on a large German
cohort [9]. These findings indicate that BMI is better able to
account for the differences in body fat content and distribution in
men and women, a conclusion that conflicts with recent data in a
cohort of women with familial lipodystrophy, which suggested that
BAI may be a more sensitive mode of estimating adiposity [11].
Our findings suggest that sex-adjustment of current BMI cutoffs
for defining normal weight, overweight, and obese, might yield a
more accurate assessment of body adiposity than either BMI or
BAI as currently used.
BAI was designed specifically as a single equation that could
predict body adiposity in pooled analyses of both genders. It was
not designed as a tool to predict cardiometabolic risk. Our current
data verifies that BAI is a stronger correlate of PBF than BMI in
sex-pooled data, providing further support that BAI achieves what
it was designed to do. Recent literature has raised questions about
sex-specific bias in the variables used to derive BAI [9]. We found
that among the characteristics considered for inclusion in the BAI
equation (i.e. waist, hip, height, and weight), hip and height did, in
fact, show the strongest correlation with PBF in sex-pooled data, in
agreement with Bergman et al. [7]. However, as described in
recent articles and the results herein, the correlation between
height and adiposity is lost in sex-stratified analysis, suggesting that
the correlation between height and PBF may be driven by sex-
differences in these variables [9,19] (Figure S1). However, the
significance of this finding with respect to the comparative analysis
of BAI and BMI is unclear, given that both indices incorporate
height into their calculations.
We acknowledge limitations in our study, including the lack of
racial and ethnic diversity in our cohort. We studied Mexican
Americans, as did Bergman et al. [7], which provided us with the
ability to test BAI’s performance in a population representative of
its derivation group. Nevertheless, the results herein may not apply
to other ethnic groups. Additionally, our study did not have access
to longitudinal follow-up data on study subjects, which would have
provided us with cardiovascular and metabolic disease outcomes,
such as incident myocardial infarction and diabetes. Further
studies are needed to examine BAI as it relates to disease
outcomes, and to clarify any other clinical role that BAI may play
in the evaluation of obesity. At the present time, if the goal is
assessment of cardiometabolic risk, BMI is a more suitable tool
than BAI.
Supporting Information
Figure S1 Relationship between height and percent
body fat (PBF) in sex-pooled (A) and sex-stratified (B)
analyses.
(TIFF)
Figure 1. Relationship of percent body fat (PBF) with body adiposity index (BAI) and body mass index (BMI) in men and women. A.
BAI versus PBF. B. BMI versus PBF. The graphs are generated on untransformed data for the BAI and BMI variables, while the main analyses in our
study are based on log transformations of these variables. Therefore, the correlation coefficients (r) here are slightly different than those reported
elsewhere in the text.
doi:10.1371/journal.pone.0065954.g001
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Table S1 Correlations of anthropometric measure-
ments with cardiometabolic risk factors taking family
relationships into consideration
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Table S2 Comparison of correlation coefficients be-
tween cardiometabolic risk factors and hip circumfer-
ence versus weight.
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